Cargando…

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data

Limited data are available on the responses to heterologous vaccine regimens for SARS-CoV-2, especially among countries using inactivated and adenoviral-vectored vaccines. A total of 77 participants who received heterologous inactivated COVID-19 vaccine (CoronaVac) and adenoviral-vectored vaccine (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wanlapakorn, Nasamon, Suntronwong, Nungruthai, Phowatthanasathian, Harit, Yorsaeng, Ritthideach, Thongmee, Thanunrat, Vichaiwattana, Preeyaporn, Auphimai, Chompoonut, Wongsrisang, Lakkhana, Klinfueng, Sirapa, Sudhinaraset, Natthinee, Poovorawan, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013645/ https://www.ncbi.nlm.nih.gov/pubmed/35465981 http://dx.doi.org/10.1016/j.vaccine.2022.04.043

Ejemplares similares

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
por: Yorsaeng, Ritthideach, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023
por: Chansaenroj, Jira, et al.
Publicado: (2023)

Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Climate factors influence seasonal influenza activity in Bangkok, Thailand
por: Suntronwong, Nungruthai, et al.
Publicado: (2020)

Characterizing genetic and antigenic divergence from vaccine strain of influenza A and B viruses circulating in Thailand, 2017–2020
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
por: Suntronwong, Nungruthai, et al.
Publicado: (2023)

Genetic and antigenic divergence in the influenza A(H3N2) virus circulating between 2016 and 2017 in Thailand
por: Suntronwong, Nungruthai, et al.
Publicado: (2017)

Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015
por: Tewawong, Nipaporn, et al.
Publicado: (2017)

Respiratory syncytial virus, human metapneumovirus, and influenza virus infection in Bangkok, 2016-2017
por: Thongpan, Ilada, et al.
Publicado: (2019)

Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination
por: Wanlapakorn, Nasamon, et al.
Publicado: (2016)

Antibodies to Bordetella pertussis antigens in maternal and cord blood pairs: a Thai cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2017)

Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens
por: Bureerug, Teeraporn C., et al.
Publicado: (2023)

Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey
por: Wanlapakorn, Nasamon, et al.
Publicado: (2019)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

The impact of COVID-19 and control measures on public health in Thailand, 2020
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
por: Luangdilok, Sutima, et al.
Publicado: (2022)

Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019–2020
por: Wanlapakorn, Nasamon, et al.
Publicado: (2023)

Molecular epidemiology of the first wave of severe acute respiratory syndrome coronavirus 2 infection in Thailand in 2020
por: Puenpa, Jiratchaya, et al.
Publicado: (2020)

Assessing Antigenic Drift of Seasonal Influenza A(H3N2) and A(H1N1)pdm09 Viruses
por: Tewawong, Nipaporn, et al.
Publicado: (2015)

Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study
por: Wasitthankasem, Rujipat, et al.
Publicado: (2018)

Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy
por: Wasitthankasem, Rujipat, et al.
Publicado: (2018)

Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
por: Pratedrat, Pornpitra, et al.
Publicado: (2023)

Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients
por: Chansaenroj, Jira, et al.
Publicado: (2021)

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2022)

Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Chikungunya Outbreak in Bueng Kan Province, Thailand, 2013
por: Wanlapakorn, Nasamon, et al.
Publicado: (2014)

Large-scale outbreak of Chikungunya virus infection in Thailand, 2018–2019
por: Khongwichit, Sarawut, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8uikmd4mhqgrefqlcagfr0vmp3